Bladder Cancer Expert Debates Videos

Perioperative Immunotherapy Versus Risk-Adapted Adjuvant Therapy in MIBC - Patrizia Giannatempo & Thomas Powles

Managing Radiation Toxicity After Trimodal Therapy for Bladder Cancer - Antoine Van Der Heijden & Neha Vapiwala

Bladder Preservation After Neoadjuvant EV+Pembrolizumab - Bogdana Schmidt & Fernando Maluf

Cystoscopy vs Urinary Markers: A Debate on Bladder Cancer Surveillance Strategies - Jeremy Teoh & Laura Mertens

Artificial Intelligence and Machine Learning in Bladder Cancer Pathology and Clinical Decision-Making - Hikmat Al-Ahmadie & Alexandre Zlotta

Radiation vs Systemic Therapy for Isolated Pelvic Recurrence After Cystectomy - Andrea Necchi & Comron Hassanzadeh

Optimizing TURBT: Balancing Surgical Skill and Advanced Technology - Mark Tyson & Vignesh Packiam

Cystectomy vs. Bladder Preservation: Weighing Options for Muscle-Invasive Bladder Cancer - Bogdana Schmidt & Kent Mouw

Active Surveillance vs TURBT for Low-Grade Ta Bladder Cancer - Morgan Rouprêt & Laura Bukavina

ctDNA in Bladder Cancer: Prognostic Value and Ongoing Clinical Trials - Jonathan Rosenberg & Petros Grivas

Complete vs Partial TURBT for Muscle-Invasive Bladder Cancer Treatment - Fredrik Liedberg, Marco Moschini & Benjamin Pradere

Managing BCG-Unresponsive Bladder Cancer: Balancing Bladder Preservation and Cystectomy - Paolo Gontero & Maria Carmen Mir

Treatment Approaches for Node-Positive Locally Advanced Bladder Cancer - Shilpa Gupta & Felix Guerrero-Ramos

Selecting the Appropriate Urinary Diversion Method for Bladder Cancer Patients - Bernard Bochner & Arnulf Stenzl

Pros and Cons of Organ-Sparing Cystectomy in Bladder Cancer Patients: Balancing Oncologic and Functional Outcomes - Param Mariappan & Maria Carmen Mir

Debating Treatment Options for Very High-Risk Non-Muscle-Invasive Bladder Cancer: BCG vs. Radical Cystectomy - Morgan Rouprêt & Laura Mertens

Optimal TURBT: Do Skilled Urologists Really Need Photodynamic Diagnosis (PDD)? -Trinity Bivalacqua & Michael Cookson

The Management of High-Grade T1 Bladder Cancer: Joan Palou and Alfred Witjes

Highlighting 25 Years of the International Bladder Cancer Network (IBCN) - Barton Grossman

Management of Small Local Recurrence Low-grade Bladder Tumors with Negative Cytology - Marek Babjuk, Morgan Roupret & Wassim Kassouf

Choice of Urinary Diversion in Patients Undergoing Radical Cystectomy - Peter Black, Jens Bedke, and Hugh Mostafid

Optimal Therapy for Patient with T0 After Neoadjuvant Chemotherapy - Sima Porten, Ananya Choudhury, Paolo Gontero, and Kamal Pohar

A Study to Improve the Diagnosis of Bladder Cancer - BladderPath Study - Jim Catto & Gary Steinberg

TURBT Quality Indicators and Access Issues in the United Kingdom - Param Mariappan & Prashant Patel

Molecular Subtyping of Bladder Cancer: Ready for Prime Time? - Eva Comperat & Hikmat Al-Ahmadie

T2 Muscle-Invasive Bladder Cancer: Tri-Modality Therapy (TMT) versus Radical Cystectomy - Stephen Williams & Nick James

Neoadjuvant Immune-Checkpoint Inhibition Vs. Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Bladder Cancer (MIBC) - Andrea Necchi and Petros Grivas

Management of High-Grade T1 Bladder Cancer: Cystectomy versus BCG - Bernard Bochner & Paolo Gontero

Neoadjuvant Vs. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma - Alison Birtle & Surena Matin

Blue Light Cystoscopy with Cysview® & Adjuvant Perioperative Chemotherapy for Nonmuscle-Invasive Bladder Cancer - Sia Daneshmand & Trinity Bivalacqua